The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
- 30 June 2017
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (9) , 3452-3460
Abstract
CONTEXT: PCSK9 mediates the degradation of the low-density lipoprotein receptor (LDLR) thereby increasing plasma low density lipoprotein cholesterol (LDL-C). Variations in the PCSK9 gene that are associated with loss-of-function (LOF) of PCSK9 result in a greater expression of hepatic LDLR, lower concentrations of LDL-C, and protection from cardiovascular disease (CVD). Apolipoprotein-B (apo) remnants also contribute to CVD risk and are similarly cleared by the LDLR. We hypothesized that PCSK9-LOF carriers would have significantly lower fasting and postprandial remnant lipoproteins on top of lower LDL-C. OBJECTIVE: To compare fasting and postprandial concentrations of triglycerides (TG), total-apoB and apoB48 as indicators of remnant lipoprotein metabolism in PCSK9-LOF carriers with controls with no PCSK9 variants. DESIGN: Case-control, metabolic study. SETTING: Clinical Research Center of the Ottawa Hospital PARTICIPANTS: Subjects with 1 or more copies of the L10ins/A53V and/or I474V and/or R46L PCSK9 variant, and no PCSK9 variants (non-carrier controls). INTERVENTION(S): Oral fat tolerance test MAIN OUTCOMES MEASURED: Fasting and postprandial plasma TG, apoB48, total-apoB, total cholesterol, and PCSK9 were measured at 0, 2, 4, and 6 hours after an oral fat load. RESULTS: Subjects with PCSK9-LOF variants (n=22) had significantly reduced fasting LDL-C (-14%) as well as lower fasting TG (-21%) compared to non-carrier controls (n=23). LOF variants also had significantly reduced postprandial total-apoB (-17%), apoB48 (-23%), and TG (-18%). Postprandial PCSK9 declined in both LOF and non-variant groups (-24% versus -16%, respectively). CONCLUSIONS: Subjects carrying PCSK9-LOF variants had attenuated levels of fasting and postprandial TG, apoB48 and total-apoB. This may confer protection from CVD and further validate the use of PCSK9 inhibitors to lower CVD risk.Keywords
This publication has 36 references indexed in Scilit:
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)PLOS ONE, 2013
- Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populationsLipids in Health and Disease, 2013
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose dietsNutrition & Metabolism, 2013
- Postprandial lipoprotein metabolism: VLDL vs chylomicronsClinica Chimica Acta, 2011
- Unexpected roles for PCSK9 in lipid metabolismCurrent Opinion in Lipidology, 2011
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEuropean Heart Journal, 2011
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial TriglyceridemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed miceJournal of Lipid Research, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003